Increased Expression of p-GSK3β Predicts Poor Survival in T -III/IV Stage OSCC Patients.
AJCC
IHC
OSCC
T stage
pGSK3β
prognostic factors
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
21
03
2020
revised:
12
04
2020
accepted:
13
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Glycogen synthase kinase 3 beta (GSK3-β) acts either as a tumor suppressor or an oncogene in various human cancers. The present study aimed to investigate the expression and activity of p-GSK3-β (Ser9) in oral cancer patients. We investigated the levels of p-GSK3β in 152 oral cancer tissues by immunohistochemistry, and explored their prognostic impact. To investigate the role of p-GSK3β (Ser9) in OSCC progression, we first analyzed the expression levels of protein p-GSK3β in normal and oral cancer tissues using immunohistochemical staining. p-GSK3β immunostaining was detected in 32 of 152 (21.1%) oral cancer specimens. High p-GSK3β expression was significantly associated with T (III/IV) stage. Kaplan-Meier survival analysis revealed that high levels of p-GSK3β were correlated with poor survival (p=0.001) in T stage (III/IV) OSCC patients. Multivariate analyses indicated that TN stage, AJCC tumor stage, tumor differentiation status and clinical therapy, but not p-GSK3β levels, were independent prognostic factors. Significant mortality risk was found in T stage (III/IV) oral cancer patients with high levels of p-GSK3β (p=0.0006). GSK3β inactivation is a key event in oral cancer patients and targeting GSK3β might be valuable in treating oral cancer patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Glycogen synthase kinase 3 beta (GSK3-β) acts either as a tumor suppressor or an oncogene in various human cancers. The present study aimed to investigate the expression and activity of p-GSK3-β (Ser9) in oral cancer patients.
MATERIALS AND METHODS
METHODS
We investigated the levels of p-GSK3β in 152 oral cancer tissues by immunohistochemistry, and explored their prognostic impact.
RESULTS
RESULTS
To investigate the role of p-GSK3β (Ser9) in OSCC progression, we first analyzed the expression levels of protein p-GSK3β in normal and oral cancer tissues using immunohistochemical staining. p-GSK3β immunostaining was detected in 32 of 152 (21.1%) oral cancer specimens. High p-GSK3β expression was significantly associated with T (III/IV) stage. Kaplan-Meier survival analysis revealed that high levels of p-GSK3β were correlated with poor survival (p=0.001) in T stage (III/IV) OSCC patients. Multivariate analyses indicated that TN stage, AJCC tumor stage, tumor differentiation status and clinical therapy, but not p-GSK3β levels, were independent prognostic factors. Significant mortality risk was found in T stage (III/IV) oral cancer patients with high levels of p-GSK3β (p=0.0006).
CONCLUSION
CONCLUSIONS
GSK3β inactivation is a key event in oral cancer patients and targeting GSK3β might be valuable in treating oral cancer patients.
Identifiants
pubmed: 32606150
pii: 34/4/1805
doi: 10.21873/invivo.11975
pmc: PMC7439907
doi:
Substances chimiques
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
Glycogen Synthase Kinase 3
EC 2.7.11.26
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1805-1809Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Oral Maxillofac Pathol. 2018 May-Aug;22(2):180-187
pubmed: 30158769
J Cell Physiol. 2018 Feb;233(2):1300-1311
pubmed: 28516459
Nat Commun. 2017 Sep 6;8(1):465
pubmed: 28878238
Cancer Res. 2007 Aug 15;67(16):7756-64
pubmed: 17699780
Cell. 2001 Jun 29;105(7):821-4
pubmed: 11439177
Mol Cancer. 2010 Jun 11;9:144
pubmed: 20537194
J Natl Cancer Inst. 2015 Jun 10;107(9):
pubmed: 26063791
Mayo Clin Proc. 2007 Jul;82(7):878-87
pubmed: 17605971
Anticancer Agents Med Chem. 2009 Dec;9(10):1114-22
pubmed: 19925395
Oral Oncol. 2009 Jul;45(7):e45-8
pubmed: 19196543
PLoS One. 2014 Jul 01;9(7):e100947
pubmed: 24984063
Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76
pubmed: 11584304
Am J Pathol. 2012 Oct;181(4):1414-25
pubmed: 22863953
J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
pubmed: 12615961
Cancer Biomark. 2018;22(4):747-753
pubmed: 29945346
J Biol Chem. 2007 Jun 8;282(23):16989-7001
pubmed: 17438332
Int J Cancer. 2012 Sep 15;131(6):E872-83
pubmed: 22539113